Moderna raises 2026 outlook after 29% jump in quarterly revenue
Moderna's Q3 revenue rose 29% to $1.313 billion and it raised 2026 guidance, while its norovirus vaccine trial missed interim goals for early success.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Moderna's third-quarter revenue reached $1.313 billion, up 29%, and the company swung to net income of $162 million from a loss a year earlier. Based on these results, it now expects 2026 revenue growth of 15% to 25%.
At the same time, the company said its Phase 3 norovirus vaccine study did not meet the interim bar for early success. It will not enroll another cohort this season and plans to consult health authorities on what comes next. Separately, regulators cleared its mFLUSIVA shot, and its melanoma program posted positive Phase 3 data.
why it matters
For investors, the key question is whether the revenue growth holds up given the setback in the norovirus program. The raised outlook and the new clearance may support sentiment around the stock, while the failed study narrows expectations for that pipeline candidate.
market impact
Moderna shares: revenue growth and higher guidance offset by norovirus trial setback
- Moderna shares mixed — revenue growth and raised guidance offset by the norovirus setback
tags
instruments
sources
- Key facts: Outlook Up; Norovirus Miss; mFLUSIVA Approved, Melanoma Data Positive — TradingView, 7 November 2026 at 08:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗